title: PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
abstract: Bevacizumab is a humanized monoclonal antibody that binds to tumor-secreted vascular endothelial growth factor (VEGF)-A and inhibits tumor angiogenesis. In 2004, the antibody was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal carcinoma in combination with chemotherapy. This report describes the preclinical evaluation of a radioimmunoconjugate, (86)Y-CHX-A″-DTPA-bevacizumab, for potential use in Positron Emission Tomography (PET) imaging of VEGF-A tumor angiogenesis and as a surrogate marker for (90)Y-based radioimmunotherapy. Bevacizumab was conjugated to CHX-A″-DTPA and radiolabeled with (86)Y. In vivo biodistribution and PET imaging studies were performed on mice bearing VEGF-A-secreting human colorectal (LS-174T), human ovarian (SKOV-3) and VEGF-A-negative human mesothelioma (MSTO-211H) xenografts. Biodistribution and PET imaging studies demonstrated highly specific tumor uptake of the radioimmunoconjugate. In mice bearing VEGF-A-secreting LS-174T, SKOV-3 and VEGF-A-negative MSTO-211H tumors, the tumor uptake at 3 days postinjection was 13.6 ± 1.5, 17.4 ± 1.7 and 6.8 ± 0.7 % ID/g, respectively. The corresponding tumor uptake in mice coinjected with 0.05 mg cold bevacizumab were 5.8 ± 1.3, 8.9 ± 1.9 and 7.4 ± 1.0 % ID/g, respectively at the same time point, demonstrating specific blockage of the target in VEGF-A-secreting tumors. The LS-174T and SKOV3 tumors were clearly visualized by PET imaging after injecting 1.8-2.0 MBq (86)Y-CHX-A″-DTPA-bevacizumab. Organ uptake quantified by PET closely correlated (r(2) = 0.87, p = 0.64, n = 18) to values determined by biodistribution studies. This preclinical study demonstrates the potential of the radioimmunoconjugate, (86)Y-CHX-A″-DTPA-bevacizumab, for noninvasive assessment of the VEGF-A tumor angiogenesis status and as a surrogate marker for (90)Y-CHX-A″-DTPA-bevacizumab radioimmunotherapy.
authors.affiliation: Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA. tapann@gmail.com
authors.forename: Tapan K
authors.initials: TK
authors.lastname: Nayak
authors.forename: Kayhan
authors.initials: K
authors.lastname: Garmestani
authors.forename: Kwamena E
authors.initials: KE
authors.lastname: Baidoo
authors.forename: Diane E
authors.initials: DE
authors.lastname: Milenic
authors.forename: Martin W
authors.initials: MW
authors.lastname: Brechbiel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000493:pharmacokinetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000175:diagnosis; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics; D017879:Isothiocyanates / Q000493:pharmacokinetics; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000175:diagnosis; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011863:Radioimmunoassay; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D017879:Isothiocyanates; D019275:Radiopharmaceuticals; D042461:Vascular Endothelial Growth Factor A; D015021:Yttrium Radioisotopes; C467480:vascular endothelial growth factor A, mouse; C085678:N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; D000068258:Bevacizumab; D004369:Pentetic Acid
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
references.pmid: 19636328
references.citation: J Nucl Med. 2003 Jul;44(7):1148-55
references.pmid: 12843231
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Int J Cancer. 2008 May 15;122(10):2310-4
references.pmid: 18240146
references.citation: Bioconjug Chem. 1992 Jul-Aug;3(4):342-5
references.pmid: 1390990
references.citation: Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
references.pmid: 12516034
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5918-25
references.pmid: 17908988
references.citation: J Nucl Med. 2007 Aug;48(8):1313-9
references.pmid: 17631557
references.citation: Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45
references.pmid: 16832633
references.citation: Neuro Oncol. 2010 Mar;12(3):233-42
references.pmid: 20167811
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: J Magn Reson Imaging. 2009 May;29(5):1125-33
references.pmid: 19388117
references.citation: Cancer Biother Radiopharm. 2009 Apr;24(2):195-200
references.pmid: 19409041
references.citation: Bioconjug Chem. 2009 May 20;20(5):825-41
references.pmid: 19125647
references.citation: J Nucl Med. 2010 Jun;51(6):942-50
references.pmid: 20484421
references.citation: Nucl Med Biol. 2009 Jul;36(5):551-9
references.pmid: 19520296
references.citation: Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92
references.pmid: 15175836
references.citation: Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1368-76
references.pmid: 20155263
references.citation: Nucl Med Biol. 2002 Jul;29(5):599-606
references.pmid: 12088731
references.citation: Clin Cancer Res. 2009 Nov 1;15(21):6674-82
references.pmid: 19861458
references.citation: Eur J Cancer. 2008 Sep;44(13):1835-40
references.pmid: 18632262
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Ann N Y Acad Sci. 1948;4:159-70
references.pmid: 18862169
references.citation: Q J Nucl Med Mol Imaging. 2008 Jun;52(2):159-65
references.pmid: 18043538
references.citation: Eur J Nucl Med Mol Imaging. 2003 May;30(5):716-20
references.pmid: 12605273
references.citation: Nature. 2005 Dec 15;438(7070):967-74
references.pmid: 16355214
references.citation: Nat Rev Drug Discov. 2004 May;3(5):391-400
references.pmid: 15136787